Free Trial

XOMA Q2 2023 Earnings Report

XOMA logo
$30.69 -0.97 (-3.06%)
(As of 01:15 PM ET)

XOMA Earnings Headlines

XOMA (NASDAQ:XOMA) Earns Buy Rating from HC Wainwright
⭕ [URGENT] Buy Alert just triggered
My absolute favorite stock just hit a critical "buy now" trigger price.
Strategic Acquisitions and Growth Potential Bolster Xoma’s Buy Rating
See More XOMA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XOMA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XOMA and other key companies, straight to your email.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

View XOMA Profile

More Earnings Resources from MarketBeat